A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. Supplementary Figures and Tables
收藏NIAID Data Ecosystem2026-03-12 收录
官方服务：
资源简介：
Supplementary Figures 1-7. Supplementary Tables 1-5
创建时间：
2021-07-29
